As a result, the modified regimen more significantly suppresses tumor growth in vivo than solution‐based conventional MAP, suggesting that HSA‐TPP NC‐assisted MAP may be a promising strategy for osteosarcoma treatment. The gene discussed is TNS3; the disease is neoplasm.